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Increasing skin cancer incidence in young, affluent, 
urban populations: a challenge for prevention
Deady et al. state that nonmelanoma skin cancer (NMSC) is the 
most common cancer in white populations, but is registered 
inconsistently by population-based registries. Their stated aim 
in this study was to analyse the changing profile of NMSC in a 
national population in Ireland, to interpret evolving patterns of 
sun exposure and to recommend measures to reduce risk. They 
did this by analysing trends in the demographic, clinical and 
socioeconomic profile of over 50 000 cases of NMSC registered 
between 1994 and 2011 by the Irish National Cancer Registry. 
This registry aims to register all episodes of NMSC in the Irish 
population to a high degree of completeness. They found that 
the incidence of cutaneous basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC) was stable from 1994 to about 
2002, but then increased significantly (BCC more than SCC) 
in the subsequent decade. They report that the largest relative 
increases in BCC incidence were in younger populations and 
in clothed body sites. The incidence of both SCC and BCC was 
lower in rural areas. The incidence of BCC, and to a lesser extent 
SCC, increased with increasing affluence in urban, but not in 
rural areas. The authors conclude by stating that recent increases 
in skin cancers on the trunk and limbs in younger people appear 
to be related to increasing affluence and consequent leisure-
related, episodic sun exposure. They state that this population 
is at high risk of subsequent skin cancers throughout life and 
will therefore need active surveillance. They propose preventive 
programmes on the basis of their being cost-effective in lower-
ing the incidence of NMSC, and that these should be targeted at 
leisure exposures in young people. They finish with a call for the 
provision of more consistent international data on NMSC. Br J 
Dermatol 2014; 171: 324–331.
Drug survival of fumaric acid esters for psoriasis: 
a retrospective study
Ismail et al. explain that fumaric acid esters (FAEs) have now 
been used for over 30 years in the management of psoriasis. 
Their study objectives were to determine (i) drug survival of 
FAEs in patients with psoriasis, (ii) treatment-limiting adverse 
drug events and (iii) the range of effective drug doses. They 
carried out a retrospective, single-centre study assessing all 
patients commenced on FAEs between October 2003 and July 
2012. Demographic data, length of treatment, reasons for dis-
continuation of FAEs, side-effects and range of doses were all 
recorded. In total 249 patients (160 male, 64%) were included. 
The mean age at which FAEs were commenced was 44.5 years 
(range 17–82). The mean length of treatment was 28 months 
(range 1 week to 106 months). In patients who were com-
menced on FAEs ≥ 4 years before inclusion in this study, the 
4-year drug survival was 60% (64/107). FAEs were discontin-
ued in 146/249 patients (59%); this was due to lack of efficacy 
in 59/146 (40%) and gastrointestinal upset in 39/146 (27%). 
A very low dose of FAEs (< 240 mg daily) was successful in 
maintaining control of psoriasis in 26 patients (10%). The mean 
treatment duration of these patients was 64 months (range 
32–106). The authors concluded that FAEs have a 4-year drug 
survival rate of 60%, which compares favourably with reported 
4-year survival rates of 40% for etanercept and adalimumab 
and 70% for infliximab. They also conclude that longer drug 
survival is more likely in the significant subgroup of patients in 
whom a very low dose of FAEs is sufficient to control their dis-
ease, although the reasons for this are unclear. Br J Dermatol 
2014; 171: 397–402.
Reducing social anxiety associated with vitiligo: 
using clinical significance to measure the 
effectiveness of enhanced psychological self-help
Shah et al. explain that vitiligo can be associated with high levels 
of social anxiety, and yet relatively few psychological interven-
tions exist. Their aim in this study was to assess the effectiveness 
of a self-help intervention designed to reduce levels of social 
anxiety associated with vitiligo. Their study also examined 
whether augmenting self-help with specific implementation 
intentions, aimed at increasing the use of materials, aided effec-
tiveness. Their study involved 75 participants who were ran-
domized to one of three groups: cognitive behavioural self-help 
(CBSH), augmented self-help (CBSH+: CBSH with implementa-
tion intentions) or no intervention. Participants were assessed at 
baseline and after 8 weeks, on measures of social anxiety, anxi-
ety and depression, and appearance-related concern. The two 
intervention groups also completed a questionnaire evaluating 
use of, and satisfaction with, the intervention. Overall 24% of 
participants in the CBSH+ group experienced clinically signifi-
cant change on the measure of social anxiety, compared with 
8% in the CBSH group and 0% in the control group. In addition, 
58% of the control group deteriorated during the study period. 
There were no significant differences between the conditions on 
the other outcome measures. Participants reported that the self-
help leaflets were helpful. The authors concluded that their find-
ings demonstrate that augmented CBSH can result in clinically 
significant changes in social anxiety levels for a minority of peo-
ple. They state that this suggests that the augmented intervention 
has potential and might be further developed and evaluated in 
subsequent studies. Br J Dermatol 2014; 171: 332–337.
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